“Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors”, J. Anal. Oncol., vol. 4, no. 3, pp.  94–101, Jun. 2015, doi: 10.6000/1927-7229.2015.04.03.1.